Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 22 November 1991:
Vol. 254. no. 5035, pp. 1173 - 1177
DOI: 10.1126/science.1683495
Prev | Table of Contents | Next

Articles

Science, Vol 254, Issue 5035, 1173-1177
Copyright © 1991 by American Association for the Advancement of Science

articles

Recombinant toxins for cancer treatment

I Pastan and D FitzGerald

Division of Cancer Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.

Recombinant toxins target cell surface receptors and antigens on tumor cells. They kill by mechanisms different from conventional chemotherapy, so that cross resistance to conventional chemotherapeutic agents should not be a problem. Furthermore, they are not mutagens and should not induce secondary malignancies or accelerate progression of benign malignancies. They can be mass-produced cheaply in bacteria as homogeneous proteins. Either growth factor-toxin fusions or antibody-toxin fusions can be chosen, depending on the cellular target.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors.
J. H. Sampson, G. Akabani, G. E. Archer, M. S. Berger, R. E. Coleman, A. H. Friedman, H. S. Friedman, K. Greer, J. E. Herndon II, S. Kunwar, et al. (2008)
Neuro-oncol 10, 320-329
   Abstract »    Full Text »    PDF »
Eradication of Tumor Colonization and Invasion by a B Cell-Specific Immunotoxin in a Murine Model for Human Primary Intraocular Lymphoma.
Z. Li, S. P. Mahesh, D. F. Shen, B. Liu, W. O. Siu, F. S. Hwang, Q.-C. Wang, C.-C. Chan, I. Pastan, and R. B. Nussenblatt (2006)
Cancer Res. 66, 10586-10593
   Abstract »    Full Text »    PDF »
Clinical Evaluation of BR96 sFv-PE40 Immunotoxin Therapy in Canine Models of Spontaneously Occurring Invasive Carcinoma.
C. J. Henry, M. S. Buss, I. Hellstrom, K. E. Hellstrom, W. G. Brewer, J. N. Bryan, and C. B. Siegall (2005)
Clin. Cancer Res. 11, 751-755
   Abstract »    Full Text »    PDF »
A Fully Human Antitumor ImmunoRNase Selective for ErbB-2-Positive Carcinomas.
C. D. Lorenzo, A. Arciello, R. Cozzolino, D. B. Palmer, P. Laccetti, R. Piccoli, and G. D'Alessio (2004)
Cancer Res. 64, 4870-4874
   Abstract »    Full Text »    PDF »
Cytotoxic Activity of Gonadotropin-Releasing Hormone (GnRH)-Pokeweed Antiviral Protein Conjugates in Cell Lines Expressing GnRH Receptors.
W.-H. Yang, M. Wieczorck, M. C. Allen, and T. M. Nett (2003)
Endocrinology 144, 1456-1463
   Abstract »    Full Text »    PDF »
IL-13 Receptor-Targeted Cytotoxin Cancer Therapy Leads to Complete Eradication of Tumors with the Aid of Phagocytic Cells in Nude Mice Model of Human Cancer.
K. Kawakami, M. Kawakami, and R. K. Puri (2002)
J. Immunol. 169, 7119-7126
   Abstract »    Full Text »    PDF »
An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells.
P. P. Ng, J. S. Dela Cruz, D. N. Sorour, J. M. Stinebaugh, S.-U. Shin, D. S. Shin, S. L. Morrison, and M. L. Penichet (2002)
PNAS 99, 10706-10711
   Abstract »    Full Text »    PDF »
Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides.
T. Decker, S. Hipp, R. J. Kreitman, I. Pastan, C. Peschel, and T. Licht (2002)
Blood 99, 1320-1326
   Abstract »    Full Text »    PDF »
Internalization Property of Interleukin-4 Receptor {alpha} Chain Increases Cytotoxic Effect of Interleukin-4 Receptor-targeted Cytotoxin in Cancer Cells.
K. Kawakami, M. Kawakami, P. Leland, and R. K. Puri (2002)
Clin. Cancer Res. 8, 258-266
   Abstract »    Full Text »    PDF »
Lowering the Isoelectric Point of the Fv Portion of Recombinant Immunotoxins Leads to Decreased Nonspecific Animal Toxicity without Affecting Antitumor Activity.
M. Onda, S. Nagata, Y. Tsutsumi, J. J. Vincent, Q.-c. Wang, R. J. Kreitman, B. Lee, and I. Pastan (2001)
Cancer Res. 61, 5070-5077
   Abstract »    Full Text »    PDF »
Intratumoral Administration of Recombinant Circularly Permuted Interleukin-4-Pseudomonas Exotoxin in Patients with High-Grade Glioma.
R. W. Rand, R. J. Kreitman, N. Patronas, F. Varricchio, I. Pastan, and R. K. Puri (2000)
Clin. Cancer Res. 6, 2157-2165
   Abstract »    Full Text »
Compatible-Solute-Supported Periplasmic Expression of Functional Recombinant Proteins under Stress Conditions.
S. Barth, M. Huhn, B. Matthey, A. Klimka, E. A. Galinski, and A. Engert (2000)
Appl. Envir. Microbiol. 66, 1572-1579
   Abstract »    Full Text »
Pharmacokinetics and Antitumor Activity of a Bivalent Disulfide-stabilized Fv Immunotoxin with Improved Antigen Binding to erbB2.
T. K. Bera, J. Viner, E. Brinkmann, and I. Pastan (1999)
Cancer Res. 59, 4018-4022
   Abstract »    Full Text »    PDF »
Toxicologic Pathology of Cytokines, Cytokine Receptors, and Other Recombinant Human Proteins: Development of a Recombinant Interleukin-4-Pseudomonas Exotoxin for Therapy of Glioblastoma.
R. K. Puri (1999)
Toxicol Pathol 27, 53-57
   Abstract »    PDF »
Diphtheria Toxin Fused to Granulocyte-Macrophage Colony-Stimulating Factor Eliminates Acute Myeloid Leukemia Cells With the Potential to Initiate Leukemia in Immunodeficient Mice, But Spares Normal Hemopoietic Stem Cells.
W. Terpstra, H. Rozemuller, D. A. Breems, E. J.C. Rombouts, A. Prins, D. J.P. FitzGerald, R. J. Kreitman, J. J. Wielenga, R. E. Ploemacher, B. Lowenberg, et al. (1997)
Blood 90, 3735-3742
   Abstract »    Full Text »    PDF »
Recombinant Toxins Containing Human Granulocyte-Macrophage Colony-Stimulating Factor and Either Pseudomonas Exotoxin or Diphtheria Toxin Kill Gastrointestinal Cancer and Leukemia Cells.
R. J. Kreitman and I. Pastan (1997)
Blood 90, 252-259
   Abstract »    Full Text »    PDF »
Peptide-specific killing of antigen-presenting cells by a recombinant antibody-toxin fusion protein targeted to major histocompatibility complex/peptide class I complexes with T cell receptor-like specificity.
Y. Reiter, A. Di Carlo, L. Fugger, J. Engberg, and I. Pastan (1997)
PNAS 94, 4631-4636
   Abstract »    Full Text »    PDF »
Adenocarcinoma Cells Are Targeted by the New GnRH-PE66 Chimeric Toxin through Specific Gonadotropin-releasing Hormone Binding Sites.
A. Nechushtan, S. Yarkoni, I. Marianovsky, and H. Lorberboum-Galski (1997)
J. Biol. Chem. 272, 11597-11603
   Abstract »    Full Text »    PDF »
T Cell-targeted Immunofusion Proteins from Escherichia coli.
M. Better, S. L. Bernhard, R. E. Williams, S. D. Leigh, R. J. Bauer, A. H. C. Kung, S. F. Carroll, and D. M. Fishwild (1995)
J. Biol. Chem. 270, 14951-14957
   Abstract »    Full Text »    PDF »
Growth factors and cancer.
S. Aaronson (1991)
Science 254, 1146-1153
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)